Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, December 26, 2018
Fri, December 21, 2018
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
[ Fri, Dec 21st 2018
] - WOPRAI
Thu, December 20, 2018
[ Thu, Dec 20th 2018
] - WOPRAI
[ Thu, Dec 20th 2018
] - WOPRAI
[ Thu, Dec 20th 2018
] - WOPRAI
[ Thu, Dec 20th 2018
] - WOPRAI
[ Thu, Dec 20th 2018
] - WOPRAI
Wed, December 19, 2018
[ Wed, Dec 19th 2018
] - WOPRAI
[ Wed, Dec 19th 2018
] - WOPRAI
[ Wed, Dec 19th 2018
] - WOPRAI
[ Wed, Dec 19th 2018
] - WOPRAI
[ Wed, Dec 19th 2018
] - WOPRAI
[ Wed, Dec 19th 2018
] - WOPRAI
Matthew Harrison Maintained (BIIB) at Buy with Increased Target to $401 on, Dec 19th, 2018
Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $394 to $401 on, Dec 19th, 2018.
Matthew has made no other calls on BIIB in the last 4 months.
There are 3 other peers that have a rating on BIIB. Out of the 3 peers that are also analyzing BIIB, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, October 19th, 2018
These are the ratings of the 2 analyists that currently disagree with Matthew
- Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $436 on, Wednesday, October 24th, 2018
- Alethia Young of "Cantor Fitzgerald" Initiated at Buy and Held Target at $400 on, Monday, October 1st, 2018
